Michael G. Fradley, MD: How Does Atrial Fibrillation Affect Outcomes and Health-Care Utilization Among Patients With CLL?
ASCO 2026
Michael G. Fradley, MD, of the University of Pennsylvania School of Medicine, discusses findings from a study which evaluated impact of atrial fibrillation on cardiovascular outcomes (stroke, bleeding, heart failure) and health-care utilization in patients with chronic lymphocytic leukemia (CLL) overall, by age, and by treatment (Abstract 7042).
Related Videos
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
The ASCO Post Staff
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).
Antonio Llombart-Cussac, MD, PhD, of Medica Scientia Innovation Research (MEDSIR), discusses the ongoing ADELA study, a double-blind, placebo-controlled, randomized phase III trial of elacestrant plus everolimus vs elacestrant plus placebo in patients with estrogen receptor (ER)-positive HER2-negative advanced breast cancer with ESR1-mutated tumors who experienced disease progression on endocrine therapy plus CDK4/6 inhibition (Abstract TPS1154).
ClinicalTrials.gov identifier: NCT06382948
The ASCO Post Staff
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517).
The ASCO Post Staff
Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international randomized controlled trial comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment in mostly node-positive patients with high clinical risk ER-positive HER2-negative early breast cancer (Abstract 500).
